Blocking checkpoint pathways has been extensively investigated as a therapeutic strategy in cancer, leading to the recent approval of PD-1 and PD-L1 blocking antibodies for the treatment of NSCLC.45 Here, CD274 is linked to non-small cell lung carcinoma.